liu.seSearch for publications in DiVA
Change search
ReferencesLink to record
Permanent link

Direct link
Reduced retinoic acid-sensitivities of nuclear receptor corepressor binding to PML- and PLZF-RARalpha underlie molecular pathogenesis and treatment of acute promyelocytic leukemia
Chester Beatty Laboratories, London, UK.
Chester Beatty Laboratories, London, UK.
Chester Beatty Laboratories, London, UK.
Linköping University, Department of Biomedicine and Surgery, Cell biology. Linköping University, Faculty of Health Sciences.ORCID iD: 0000-0003-3927-4394
Show others and affiliations
1998 (English)In: Blood, ISSN 0006-4971, E-ISSN 1528-0020, Vol. 91, no 8, 2634-2642 p.Article in journal (Refereed) Published
Abstract [en]

Typical acute promyelocytic leukemia (APL) is associated with expression of the PML-RARalpha fusion protein and responsiveness to treatment with all-trans retinoic acid (ATRA). A rare, but recurrent, APL has been described that does not respond to ATRA treatment and is associated with a variant chromosomal translocation and expression of the PLZF-RARalpha fusion protein. Both PML- and PLZF-RARalpha possess identical RAR sequences and inhibit ATRA-induced gene transcription as well as cell differentiation. We now show that the above-mentioned oncogenic fusion proteins interact with the nuclear receptor corepressor N-CoR and, in comparison with the wild-type RARalpha protein, their interactions display reduced sensitivities to ATRA. Although pharmacologic concentration of ATRA could still induce dissociation of N-CoR from PML-RARalpha, it had a very little effect on its association with the PLZF-RARalpha fusion protein. This ATRA-insensitive interaction between N-CoR and PLZF-RARalpha was mediated by the N-terminal PLZF moiety of the chimera. It appears that N-CoR/histone deacetylase corepressor complex interacts directly in an ATRA-insensitive manner with the BTB/POZ-domain of the wild-type PLZF protein and is required, at least in part, for its function as a transcriptional repressor. As the above-noted results predict, histone deacetylase inhibitors antagonize oncogenic activities of the PML-RARalpha fusion protein and partially relieve transcriptional repression by PLZF as well as inhibitory effect of PLZF-RARalpha on ATRA response. Taken together, our results demonstrate involvement of nuclear receptor corepressor/histone deacetylase complex in the molecular pathogenesis of APL and provide an explanation for differential sensitivities of PML- and PLZF-RARalpha-associated leukemias to ATRA.

Place, publisher, year, edition, pages
American Society of Hematology , 1998. Vol. 91, no 8, 2634-2642 p.
National Category
Medical and Health Sciences
URN: urn:nbn:se:liu:diva-99886ISI: 000073012000002PubMedID: 9531570OAI: diva2:658736
Available from: 2013-10-22 Created: 2013-10-22 Last updated: 2013-10-31Bibliographically approved

Open Access in DiVA

No full text

Other links

PubMedLink to article

Search in DiVA

By author/editor
Söderström, Mats
By organisation
Cell biologyFaculty of Health Sciences
In the same journal
Medical and Health Sciences

Search outside of DiVA

GoogleGoogle Scholar
The number of downloads is the sum of all downloads of full texts. It may include eg previous versions that are now no longer available

Altmetric score

Total: 41 hits
ReferencesLink to record
Permanent link

Direct link